GSK and Impax nearing US and European regulatory filings for Parkinson's drug
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Impax Pharmaceuticals are gearing up for US and European regulatory submissions of, IPX066, an extended release capsule formulation of carbidopa-levodopa (CD-LD) for the treatment of the motor symptoms of Parkinson’s disease after reporting positive top-line from a third Phase III trial of the drug.